CELLECTAR BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

ITEM 7.01 REGULATION FD DISCLOSURE

On January 27, 2021, we issued a press release announcing that the European Medicines Agency has adopted a positive opinion for CLR 131 orphan designation for the treatment of Waldenstrom's Macroglobulinemia (WM).

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits



 Number    Title
  99.1       Press release dated January 27, 2021, titled "Cellectar Receives
           Orphan Drug Designation from the European Commission for CLR 131 in
           Waldenstrom's Macroglobulinemia"




                                       2

© Edgar Online, source Glimpses